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Relatively little work has been published concerning associations between pharmacogenetic polymorphisms and spontaneous disorders. The available knowledge about the acetylator polymorphism in this regard has recently been surveyed. 4 An early paper5 pointed out that in a series of 28 Finnish diabetics there was an unexpectedly high frequency of rapid acetylators. Omitting this index series an analysis of the six series subsequently published has been made in table 1. For the UK population three series of diabetics have been XN-, Xwy- pooled, and a large control population has been assembled from various publications as previously described.4 There was no heterogeneity between the series (all of which were European in origin) in that they all showed some increase in frequency of rapid acetylators among diabetics as compared with their own control groups. The mean relative incidence is about 1-6. Diabetes is a common disorder among Saudi Arabians. One notable differentiating clinical feature is the ability of many diabetics to tolerate a grossly raised plasma glucose concentration without symptoms. 14 The present study was undertaken to see if there was an association between either acetylator phenotype and diabetes in Saudi Arabians, and to see how the result compared with the association known in Europeans.
Methods
Diabetics studied were inpatients and outpatients of the Riyadh Armed Forces Hospital. All gave informed consent for the acetylator phenotyping test 100, The frequency of the allele controlling slow acetylation in the healthy control subjects is 0 8185.
The 'relative incidence' has been calculated for all the diabetics versus the controls in the same way as in table 1 so that an association between diabetes The allele frequency in the controls is similar to that previously described in surveys of Saudi Arabians'8 and other adjacent Middle Eastern populations. 9 This is of interest because the present subjects were Saudi nationals mainly from the central and southern regions, whereas the previous surveys had been conducted from the more heterogeneous populations in the western region.
In the population of Saudi diabetics there is a significant association between slow acetylation and type I diabetes.
It might be postulated that the phenotyping results in type I diabetics might have been affected in some way by the fact that they were on insulin treatment. This idea has been disproved by comparing the phenotype frequencies in type II diabetics who were and who were not receiving insulin.
In 34 in the former category there were 10 rapid acetylators, and in 42 in the latter category there were 15 rapid acetylators (Xl=0(34).
The analysis of diabetics in table 1 pooled both types of diabetes together. This was done because it is not possible consistently to disentangle the two types from the published series. An attempt to show the breakdown is shown in table 6 . where it is clear that there is a very high frequency of rapid acetylators in European type I diabetics.
The present preliminary series suggests that as far as the association with the acetylator polymorphism is concerned, type I Saudi diabetics are quite different from type I European diabetics. Further series will be required to confirm or refute the present finding.
There is one appealing feature in studying associations of pharmacogenetic polymorphisms with spontaneous disorders. This is because the biochemical 
